Literature DB >> 3798026

Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients.

A Waage, T Espevik, J Lamvik.   

Abstract

With a bioassay sensitive for recombinant tumour necrosis factor at a concentration of 10(-4) ng/ml, we were able to detect tumour necrosis factor-like cytotoxicity in serum from three patients in the initial phase of septicaemia. The cytotoxic activity corresponded to a concentration of recombinant tumour necrosis factor of 2 X 10(-2)-3 X 10(-3) ng/ml serum. The concentration in cerebrospinal fluid was estimated to be three times higher than in serum. In 23 untreated patients with malignant disease of varying origin and stage, including two patients with severe cachexia, we were not able to detect tumour necrosis factor-like cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3798026     DOI: 10.1111/j.1365-3083.1986.tb02194.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  17 in total

1.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.

Authors:  F D Pagani; L S Baker; C Hsi; M Knox; M P Fink; M S Visner
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients.

Authors:  M Maltoni; L Fabbri; O Nanni; E Scarpi; L Pezzi; E Flamini; A Riccobon; S Derni; G Pallotti; D Amadori
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

3.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia.

Authors:  G Strassmann; M Fong; J S Kenney; C O Jacob
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Experimental Sepsis Severity Score Associated to Mortality and Bacterial Spreading is Related to Bacterial Load and Inflammatory Profile of Different Tissues.

Authors:  Muryel Carvalho Gonçalves; Verônica Vargas Horewicz; Débora Denardin Lückemeyer; Arthur Silveira Prudente; Jamil Assreuy
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

5.  Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.

Authors:  R Landmann; U Keilholz; C Scheibenbogen; M Brockhaus; H Gallati; H Denz; M Bargetzi; C Ludwig
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations.

Authors:  D G Remick; R M Strieter; M K Eskandari; D T Nguyen; M A Genord; C L Raiford; S L Kunkel
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

7.  Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture.

Authors:  G K Wollenberg; L E DeForge; G Bolgos; D G Remick
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

8.  The effects of recombinant tumour necrosis factor (cachectin) on metabolism in isolated rat adipocyte, hepatocyte and muscle preparations.

Authors:  A M Rofe; R A Conyers; R Bais; J R Gamble; M A Vadas
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

9.  Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy.

Authors:  Jan Staelens; Ben Wielockx; Leen Puimège; Frans Van Roy; Jean-Louis Guénet; Claude Libert
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

10.  Exacerbation of toxic effects by endotoxin contamination of recombinant human tumor necrosis factor.

Authors:  Y Ozaki; T Oyama; S Kume
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.